Business

Antibiotics in Focus as India Intensifies Battle Against AMR

The framework recommends fast-tracking approvals for new antibiotics, a blanket ban on over-the-counter sales, stamping prescriptions to prevent repeat use, and deploying state-level digital systems to track antimicrobial sales in real time. These measures are designed to strengthen India’s response to AMR under the National Action Plan on Antimicrobial Resistance (NAPAMR).

• By Newsdesk
• New Delhi
• Jan 11, 2026

Business

As antimicrobial resistance (AMR) escalates into a serious public health and economic challenge, India’s apex drug regulator is moving to tighten oversight across the entire antibiotics ecosystem from research and approvals to sales and post-market monitoring. Drawing on a long-awaited expert committee report, the proposed regulatory overhaul aims to curb misuse while accelerating innovation, according to government officials and documents reviewed.

The framework recommends fast-tracking approvals for new antibiotics, a blanket ban on over-the-counter sales, stamping prescriptions to prevent repeat use, and deploying state-level digital systems to track antimicrobial sales in real time. These measures are designed to strengthen India’s response to AMR under the National Action Plan on Antimicrobial Resistance (NAPAMR).

A high-level subcommittee of the Drugs Consultative Committee (DCC) has submitted its report to the Central Drugs Standard Control Organisation (CDSCO), listing more than a dozen priority actions for implementation. The recommendations come at a time when India’s $50-billion pharmaceutical industry is expanding rapidly, increasing the risk of inappropriate antibiotic use and accelerating resistance.

India first rolled out its national AMR action plan in 2017, with Phase 2.0 covering 2025–29 launched last year. The latest proposals signal a strategic shift towards closer regulatory intervention at every stage of a medicine’s lifecycle—from laboratory development to dispensing at neighbourhood pharmacies.

Minutes from the 67th DCC meeting held in New Delhi on November 17 show that the panel reviewed the subcommittee’s findings and advised the CDSCO to circulate the report to all states for necessary action. Queries sent to the health ministry and the CDSCO did not elicit responses by press time.

The urgency is underscored by mounting health and economic costs. Data from the National Centre for Disease Control estimates that AMR directly causes around 267,000 deaths annually in India. Globally, a 2017 World Bank report warned that unchecked resistance could drain trillions of dollars through higher healthcare spending and productivity losses. For India, a 2024 study by the Centre for Global Development projected potential economic losses of $21 billion by mid-century if superbugs remain uncontrolled.

Among the key recommendations are mandatory computerised billing and CCTV surveillance at wholesale and retail drug outlets, along with annual reviews of antimicrobial classifications to regulate restricted marketing in India’s $2.9-billion antibiotics market.

Environmental safeguards also feature prominently. Improper disposal of unused or expired antibiotics, often discarded in household waste or flushed into drains—has been identified as a contributor to drug-resistant pathogens in the environment. To address this, the report proposes an Extended Producer Responsibility (EPR) framework to ensure safe collection and disposal of antibiotic waste, coupled with stricter inspections of manufacturing facilities to enforce biomedical waste management norms.

Together, these measures reflect a comprehensive attempt to slow the spread of resistance while preserving the effectiveness of life-saving medicines for the future.